Shots:

• Aerogen Pharma to receive $20M up front and $10M equity in Nuance, along with a sum of $182.5M as potential development, regulatory, & commercial milestone payments, plus royalties on net sales within the territory
• The agreement grants Nuance the exclusive rights to develop and commercialize AeroFact in Greater China (Mainland China, Taiwan, Hong Kong, and Macau)
• AeroFact is a nasally inhaled surfactant based on a combination of the bovine lung surfactant Alveofact with a precise nasal delivery system containing Aerogen's next gen "PDAP" delivery technology and a touch-screen controller interface

Ref: PR Newswire | Image: Aerogen